Table. Association of Pretreatment Baseline Variables With pCR in 80 Patients With ERBB2-Positive Early-Stage Breast Cancer Treated With Neoadjuvant THP in the DAPHNe Clinical Trial.
| Characteristic | No. | pCR rate, % | Univariable | Multivariable | ||
|---|---|---|---|---|---|---|
| OR (95% CI) | P value | OR (95% CI) | P value | |||
| Overall cohort | 80 | 60.0 | ||||
| HER2DX pCR score (continuous variable) | 80 | NA | 1.05 (1.03-1.08) | <.001 | 1.03 (1.01-1.07) | .03 |
| HER2DX pCR score groups | ||||||
| Low | 31 | 29.0 | 1 [Reference] | NA | NA | NA |
| Medium | 22 | 63.6 | 4.30 (1.34-14.36) | .01 | NA | NA |
| High | 27 | 92.6 | 30.60 (1.30-156.90) | <.001 | NA | NA |
| HER2DX ERBB2 score (continuous variable) | 80 | NA | 1.05 (1.02-1.08) | <.001 | 1.03 (1.00-1.07) | .04 |
| HER2DX ERBB2 mRNA score | ||||||
| Low | 9 | 44.4 | 1 [Reference] | NA | NA | NA |
| Medium | 12 | 16.7 | 0.25 (0.03-1.86) | .18 | ||
| High | 59 | 71.2 | 3.09 (0.74-12-91) | .12 | ||
| Clinical tumor stage | ||||||
| cT1 | 15 | 80.0 | 1 [Reference] | NA | NA | NA |
| cT2-3 | 65 | 55.4 | 0.31 (0.08-1.20) | .09 | ||
| Clinical nodal stage | ||||||
| cN-negative | 52 | 59.6 | 1 [Reference] | NA | NA | NA |
| cN-positive | 28 | 60.7 | 1.05 (0.41-2.68) | .92 | ||
| PAM50 | ||||||
| Non–ERBB2-enriched | 34 | 35.3 | 1 [Reference] | NA | 1 [Reference] | NA |
| ERBB2-enriched | 46 | 78.3 | 6.6 (2.45-17.81) | <.001 | 2.05 (0.57-7.36) | .27 |
| ERBB2 IHC status | ||||||
| 2+ | 10 | 30.0 | 1 [Reference] | NA | NA | NA |
| 3+ | 68 | 66.2 | 4.57 (1.08-19.32) | .039 | NA | NA |
| Hormone receptor status | ||||||
| Positivea | 56 | 48.2 | 1 [Reference] | NA | 1 [Reference] | NA |
| Negative | 24 | 87.5 | 7.52 (2.01-28.10) | .003 | 1.79 (0.28-12.39) | .54 |
Abbreviations: IHC, immunohistochemistry; mRNA, messenger RNA; NA, not applicable; OR, odds ratio; PAM50, prediction analysis of microarray 50; pCR, pathologic complete response; THP, paclitaxel/trastuzumab/pertuzumab.
a
Hormone receptor–positive status was defined as estrogen receptor or progesterone receptor staining of 1% or greater in accordance with current guidelines from American Society of Clinical Oncology/College of American Pathologists.